CRISPR Therapeutics AG (NASDAQ: CRSP) Stock Today – Analysts’ Views Are Different

In the last trading session, 1.19 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.96. With the company’s per share price at $76.50 changed hands at $0.68 or 0.90% during last session, the market valuation stood at $6.25B. CRSP’s last price was a discount, traded about -86.46% off its 52-week high of $142.64. The share price had its 52-week low at $42.51, which suggests the last value was 44.43% up since then. When we look at CRISPR Therapeutics AG’s average trading volume, we note the 10-day average is 1.89 million shares, with the 3-month average coming to 2.03 million.

Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.20. If we narrow down to specifics, the data shows that 1 out of 27 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 9 recommended CRSP as a Hold, 16 felt it is a Buy and 0 rated the stock as Underweight. CRISPR Therapeutics AG’s EPS for the current quarter is expected to be -$2.21.

3 Tiny Stocks Primed to Explode
The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Instantly CRSP was in green as seen at the end of in last trading. With action -3.60%, the performance over the past five days has been red. The jump to weekly highs of 86.95 on Monday, 07/25/22 added 0.90% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.95%, with the 5-day performance at -3.60% in the red. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 17.42% up. Looking at the short shares, we see there were 10.14 million shares sold at short interest cover period of 9.06 days.

The consensus price target for the stock as assigned by Wall Street analysts is $112.41, meaning bulls need an upside of 31.95% from its current market value. According to analyst projections, CRSP’s forecast low is $46.00 with $220.00 as the target high. To hit the forecast high, the stock’s price needs a -187.58% plunge from its current level, while the stock would need to tank 39.87% for it to hit the projected low.

CRISPR Therapeutics AG (CRSP) estimates and forecasts

Data shows that the CRISPR Therapeutics AG share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 22.18% over the past 6 months, a -291.06% in annual growth rate that is considerably lower than the industry average of 0.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2022 revenue estimates. The rating firms predict current quarter revenue for CRISPR Therapeutics AG will fall -123.40%, while the growth in revenue is estimated to hit -34.70% for the next quarter. Year-over-year growth is forecast to reach -99.10% down from the last financial year.

Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of $2.17 million. 14 analysts are of the opinion that CRISPR Therapeutics AG’s revenue for the quarter ending Sep 2022 will be $2.18 million. The estimates for the next quarter sales put growth at 94.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.00%. The 2022 estimates are for CRISPR Therapeutics AG earnings to increase by 188.80%.

CRSP Dividends

CRISPR Therapeutics AG is expected to release its next quarterly earnings report between April 25 and April 29.

CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.48% of CRISPR Therapeutics AG shares while 62.57% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 63.51%. There are 62.57% institutions holding the CRISPR Therapeutics AG stock share, with ARK Investment Management, LLC the top institutional holder. As of Mar 30, 2022, the company held 12.14% of the shares, roughly 9.4 million CRSP shares worth $590.29 million.

Nikko Asset Management Americas, Inc. holds the second largest percentage of outstanding shares, with 5.96% or 4.62 million shares worth $289.98 million as of Mar 30, 2022.

Among Mutual Funds, the top two as of Feb 27, 2022 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. With 6.35 million shares estimated at $389.71 million under it, the former controlled 8.20% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 2.68% of the shares, roughly 2.07 million shares worth around $127.2 million.

Leave a Reply

Your email address will not be published. Required fields are marked *